208 related articles for article (PubMed ID: 26714478)
1. PPM1D exerts its oncogenic properties in human pancreatic cancer through multiple mechanisms.
Wu B; Guo BM; Kang J; Deng XZ; Fan YB; Zhang XP; Ai KX
Apoptosis; 2016 Mar; 21(3):365-78. PubMed ID: 26714478
[TBL] [Abstract][Full Text] [Related]
2. Silencing of PPM1D inhibits cell proliferation and invasion through the p38 MAPK and p53 signaling pathway in papillary thyroid carcinoma.
Lu ZW; Wen D; Wei WJ; Han LT; Xiang J; Wang YL; Wang Y; Liao T; Ji QH
Oncol Rep; 2020 Mar; 43(3):783-794. PubMed ID: 31922231
[TBL] [Abstract][Full Text] [Related]
3. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity.
Bulavin DV; Demidov ON; Saito S; Kauraniemi P; Phillips C; Amundson SA; Ambrosino C; Sauter G; Nebreda AR; Anderson CW; Kallioniemi A; Fornace AJ; Appella E
Nat Genet; 2002 Jun; 31(2):210-5. PubMed ID: 12021785
[TBL] [Abstract][Full Text] [Related]
4. Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice.
Nannenga B; Lu X; Dumble M; Van Maanen M; Nguyen TA; Sutton R; Kumar TR; Donehower LA
Mol Carcinog; 2006 Aug; 45(8):594-604. PubMed ID: 16652371
[TBL] [Abstract][Full Text] [Related]
5. PPM1D silencing by RNA interference inhibits proliferation and induces apoptosis in breast cancer cell lines with wild-type p53.
Pärssinen J; Alarmo EL; Karhu R; Kallioniemi A
Cancer Genet Cytogenet; 2008 Apr; 182(1):33-9. PubMed ID: 18328948
[TBL] [Abstract][Full Text] [Related]
6. PP2Cdelta (Ppm1d, WIP1), an endogenous inhibitor of p38 MAPK, is regulated along with Trp53 and Cdkn2a following p38 MAPK inhibition during mouse preimplantation development.
Hickson JA; Fong B; Watson PH; Watson AJ
Mol Reprod Dev; 2007 Jul; 74(7):821-34. PubMed ID: 17219434
[TBL] [Abstract][Full Text] [Related]
7. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
[TBL] [Abstract][Full Text] [Related]
8. Dual roles for the phosphatase PPM1D in regulating progesterone receptor function.
Proia DA; Nannenga BW; Donehower LA; Weigel NL
J Biol Chem; 2006 Mar; 281(11):7089-101. PubMed ID: 16352595
[TBL] [Abstract][Full Text] [Related]
9. PPM1D Knockdown Suppresses Cell Proliferation, Promotes Cell Apoptosis, and Activates p38 MAPK/p53 Signaling Pathway in Acute Myeloid Leukemia.
Li B; Hu J; He D; Chen Q; Liu S; Zhu X; Yu M
Technol Cancer Res Treat; 2020; 19():1533033820942312. PubMed ID: 32691668
[TBL] [Abstract][Full Text] [Related]
10. Silencing of ASPP2 promotes the proliferation, migration and invasion of triple-negative breast cancer cells via the PI3K/AKT pathway.
Wu T; Song H; Xie D; Zhao B; Xu H; Wu C; Hua K; Deng Y; Ji C; Hu J; Fang L
Int J Oncol; 2018 Jun; 52(6):2001-2010. PubMed ID: 29568874
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of the wip1 gene abrogates the p38 MAPK/p53/Wip1 pathway and silences p16 expression in human breast cancers.
Yu E; Ahn YS; Jang SJ; Kim MJ; Yoon HS; Gong G; Choi J
Breast Cancer Res Treat; 2007 Mar; 101(3):269-78. PubMed ID: 16897432
[TBL] [Abstract][Full Text] [Related]
12. A small molecule inhibitor of p53-inducible protein phosphatase PPM1D.
Yagi H; Chuman Y; Kozakai Y; Imagawa T; Takahashi Y; Yoshimura F; Tanino K; Sakaguchi K
Bioorg Med Chem Lett; 2012 Jan; 22(1):729-32. PubMed ID: 22115592
[TBL] [Abstract][Full Text] [Related]
13. The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours.
Rauta J; Alarmo EL; Kauraniemi P; Karhu R; Kuukasjärvi T; Kallioniemi A
Breast Cancer Res Treat; 2006 Feb; 95(3):257-63. PubMed ID: 16254685
[TBL] [Abstract][Full Text] [Related]
14. PPM1D phosphatase, a target of p53 and RBM38 RNA-binding protein, inhibits p53 mRNA translation via dephosphorylation of RBM38.
Zhang M; Xu E; Zhang J; Chen X
Oncogene; 2015 Nov; 34(48):5900-11. PubMed ID: 25823026
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway.
Bulavin DV; Phillips C; Nannenga B; Timofeev O; Donehower LA; Anderson CW; Appella E; Fornace AJ
Nat Genet; 2004 Apr; 36(4):343-50. PubMed ID: 14991053
[TBL] [Abstract][Full Text] [Related]
16. Nerve growth factor exerts differential effects on the growth of human pancreatic cancer cells.
Zhu ZW; Friess H; Wang L; Bogardus T; Korc M; Kleeff J; Büchler MW
Clin Cancer Res; 2001 Jan; 7(1):105-12. PubMed ID: 11205897
[TBL] [Abstract][Full Text] [Related]
17. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.
Ali AY; Abedini MR; Tsang BK
Oncogene; 2012 Apr; 31(17):2175-86. PubMed ID: 21927021
[TBL] [Abstract][Full Text] [Related]
18. Identification of differentially expressed genes after PPM1D silencing in breast cancer.
Pärssinen J; Alarmo EL; Khan S; Karhu R; Vihinen M; Kallioniemi A
Cancer Lett; 2008 Jan; 259(1):61-70. PubMed ID: 17977650
[TBL] [Abstract][Full Text] [Related]
19. The p53-induced oncogenic phosphatase PPM1D interacts with uracil DNA glycosylase and suppresses base excision repair.
Lu X; Bocangel D; Nannenga B; Yamaguchi H; Appella E; Donehower LA
Mol Cell; 2004 Aug; 15(4):621-34. PubMed ID: 15327777
[TBL] [Abstract][Full Text] [Related]
20. Reversion of trichostatin A resistance via inhibition of the Wnt signaling pathway in human pancreatic cancer cells.
Wang B; Zou Q; Sun M; Chen J; Wang T; Bai Y; Chen Z; Chen B; Zhou M
Oncol Rep; 2014 Nov; 32(5):2015-22. PubMed ID: 25224651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
